News – Page 6 – Serendipity Innovations

2017-08-22

Information about ongoing discussions and negotiations concerning out-licensing of Xbrane Biopharma AB’s (Publ) products

2017-08-22

Episurf Medical AB will exhibit at SOF 2017, held in Umeå, Sweden on August 29 – September 1

2017-08-18

Episurf Medical Interim Report 1 April – 30 June 2017

2017-08-16

Episurf Medical reaches milestone of 250 implants

2017-08-10

Diamorph AB (publ) to redeem its outstanding bonds in their entirety

2017-07-26

Management group changes in Episurf Medical

2017-07-24

Xbrane Biopharma AB: Spherotide granted Market Authorization in Iran

2017-07-20

Episurf Medical reports brief clinical update

2017-07-20

Episurf Medical has become an approved supplier to Spire Healthcare, one of the UK’s largest independent hospital providers

2017-07-19

Another preclinical paper on the Episealer implant published

2017-07-11

Case-report with clinical data of Episealer patient published

2017-07-11

Episurf Medical: Dennis D. Stripe to re-assume the position as Non-executive Chairman of the Board

2017-07-07

Complementary information on Xbrane Biopharma AB’s (publ) long-term share savings program for employees

2017-06-30

OrganoClick selected to achieve the United Nation’s sustainable development goals

2017-06-21

Insider transactions in Episurf Medical

2017-06-16

OrganoClick has been granted SEK 2.3 million by Vinnova for the development of a biocomposite material for furniture and furnishings in public spaces

2017-06-12

Episurf Medical obtains further granted patent in Europe

2017-06-07

Episurf Medical appoints Dr Michael Manley special advisor for US strategy

2017-06-02

Episurf Medical’s Board names Pål Ryfors new CEO and appoints new CFO

2017-05-31

Resolutions at OrganoClick Annual General Meeting

2017-05-24

Xbrane Biopharma announces a directed new share issue of SEK 20 million

2017-05-22

Summary from Annual General Meeting of Episurf Medical AB (publ)

2017-05-22

Minutes from Xbrane Biopharma AB’s (publ) Annual General Meeting

2017-05-22

OrganoClick’s subsidiary OrganoWood gets its biggest project order ever

2017-05-18

Xbrane Biopharma releases interim report for the period January – March 2017

2017-05-15

Episurf Medical continues its communication with the US Food and Drug Administration (FDA) regarding appropriate route for market acceptance in the US

2017-05-15

Episurf Medical Interim Report 1 January – 31 March, 2017

2017-05-11

Episurf Medical reaches milestone of 200 implants

2017-05-10

OrganoClick AB (publ) publishes its interim report for Q1 2017

2017-05-09

OrganoClick AB publishes its annual report for 2016

page 6 of 10